Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer

Key takeaways

• Imdelltra plus Imfinzi delivers a notable survival benefit in extensive‑stage small‑cell lung cancer, potentially reshaping treatment standards.
• 58% reduction in death risk
• 21.1 months median overall survival (combo)
• 12.7 months median overall survival (Imfinzi)

What happened

Amgen Inc. (AMGN) announced interim Phase 3 results for its drug Imdelltra combined with AstraZeneca’s (AZN) Imfinzi, showing a 58% reduction in death risk for extensive‑stage small‑cell lung cancer patients receiving first‑line maintenance therapy. The DeLLphi‑305 study reported median overall survival of 21.1 months versus 12.7 months with Imfinzi alone, and a 66% lower risk of disease progression or death. The combination also produced a 26.4% objective response rate compared with 4.1% for…

Why it matters

The results suggest a significant survival advantage for a difficult‑to‑treat lung cancer population, potentially positioning the combo as a new standard of care. The 8‑month median survival gain and high one‑year survival rate could drive clinical adoption and influence payer coverage decisions. Strong efficacy…

Short-term and longer-term

Short-term. In the next few days, watch for any updates on regulatory filings or pricing discussions that could affect the combo’s market entry.

Longer-term. Over the coming months, the combo’s strong efficacy across subgroups could expand Amgen’s and AstraZeneca’s revenue streams and strengthen their oncology pipelines.